Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy
Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy
复制标题
DOI：
10.1002/ijc.25454
复制
发表时间：
2011-03-15
影响因子：
6.4
通讯作者：
Erguen, Sueleyman
中科院分区：
文献类型：
--
作者：
Szarvas, Tibor;Becker, Markus;Erguen, Sueleyman
基质金属蛋白酶-7（MMP-7）组织表达和血清浓度升高已被证明与癌症进展和转移相关。本研究的目的是评估临床局限性前列腺癌患者术前血清循环MMP-7水平的预后价值。此外，我们还比较了器官局限性前列腺癌和转移性前列腺癌患者血清MMP-7水平。使用酶联免疫吸附试验测定了93名局限性前列腺癌患者、13名远处骨转移患者和19名对照血清中的MMP-7水平。将结果与临床随访数据进行比较。我们没有发现患者和对照组之间MMP-7血清水平的任何显著差异（p = 0.268）。有远处转移者血清MMP-7浓度显著升高（P < 0.001）。对于远处前列腺癌转移的检测，使用3.7 ng/ml的截止值，观察到69%的特异性和92%的灵敏度。多变量分析确定高MMP-7血清浓度作为前列腺癌相关死亡的独立危险因素，在术前和术后模型（p = 0.003和0.018，分别）。此外，预测模型的评估表明，将血清MMP-7水平添加到术前可用的预测因子中可以提高预后准确性（当纳入MMP-7时，一致性指数从0.631增加到0.734）。基于这些，我们得出结论，MMP-7是识别转移性前列腺癌患者的潜在标志物。在临床局限性前列腺癌中，MMP-7可以提供独立的预后信息，从而有助于优化治疗决策。
Elevated matrix metalloproteinase-7 (MMP-7) tissue expression and serum concentration have been shown to be associated with cancer progression and metastasis. The aim of our study was to assess the prognostic value of preoperative circulating MMP-7 levels in serum samples of patients with clinically localized prostate cancer. Furthermore, we compared the serum MMP-7 levels between patients with organ confined and metastatic prostate cancer. MMP-7 levels were measured in 93 patients with localized prostate cancer, 13 patients with distant bone metastasis and in sera of 19 controls using enzyme-linked immunosorbent assay. The results were compared to the clinical follow-up data. We did not find any significant difference in MMP-7 serum levels between patients and controls (p = 0.268). Circulating MMP-7 serum concentration was significantly elevated in patients with distant metastasis (p < 0.001). For the detection of distant prostate cancer metastasis, using a cut-off value of 3.7 ng/ml, a specificity of 69% and a sensitivity of 92% were observed. Multivariate analysis identified high MMP-7 serum concentration as an independent risk factor for prostate cancer-related death both in a preoperative and a postoperative model (p = 0.003 and 0.018, respectively). Furthermore, the evaluation of predictive models revealed that addition of serum MMP-7 levels to the preoperatively available predictors improves prognostic accuracy (the concordance index increased from 0.631 to 0.734 when MMP-7 was included). Based on these, we concluded that MMP-7 is a potential marker to identify patients with metastatic prostate cancer. In clinically localized prostate cancer, MMP-7 may provide independent prognostic information, thereby helping to optimize therapy decisions.